Big Basket of Baffoons

Lucy Barnes

Big Basket of Baffoons

40 years later they say we need a new

Lyme test with $$$ for them in the deal!

FORTY YEARS AFTER THE FACT... They finally admit we need new Lyme tests since the ones we have been using, that they've been swearing by, recommending, promoting and have patents on, aren't really good. Good timing too because most of these article authors (if not all) have been sucking down research money to develop a better test and get their patents filed.

QUOTE On Current Tests- "These serologic tests cannot distinguish active infection, past infection, or reinfection. Reliable direct-detection methods for active B. burgdorferiinfection have been lacking in the past but are needed and appear achievable."

Better Known of The Long Time Offenders- Schutzer, Dattwyler, Fikrig, Gerald, Marques, Mead, Steere and more baffoons. CDC, Mass General, Yale, NY Medical College, Univ. of Maryland, Rutgers, FDA, NIH, George Mason Univ, NY State DOH, and more buffoons. Full lists below.

Published in the Infectious Diseases Society of America's Journal- Clinical Infectious Diseases. One of the editors of the journal is Gary WORMSER. Another is Stanley PLOTKIN- the infamous vaccine pirateer.

To Sum It Up...

QUOTE- "This article was developed after a September 2016 meeting at the Cold Spring Harbor Laboratory Banbury Center and subsequent discussions to assess current and potentially new laboratory tests for the diagnosis of Lyme disease.

The participants were from industry, academia, and government, with extensive experience in clinical and laboratory aspects of Lyme disease and other infectious diseases, as well as participants with regulatory experience in the clearance of diagnostic tests.

The emphasis of the meeting was on diagnostic testing platforms for early Lyme disease, since current serologic tests are insensitive during the first several weeks of infection.

There was no intent to take a vote, advocate for one test product over another, or reach a consensus during the meeting; rather, there was discussion of research findings that support or challenge particular diagnostic concepts.

What emerged was a recognition that improved approaches to serologic testing were now available [4] and that the technology for direct detection of bacterial proteins or DNA has advanced to the point that it is evaluable in Lyme disease. If the technology meets scientific rigor, these tests could become future diagnostic assays."


October 2018 Study

https://www.ncbi.nlm.nih.gov/pubmed/30307486


Meet the Big Baffoons

Schutzer SE1, Body BA2, Boyle J3, Branson BM4, Dattwyler RJ5, Fikrig E6, Gerald NJ7, Gomes-Solecki M8, Kintrup M9, Ledizet M10, Levin AE11, Lewinski M12, Liotta LA13, Marques A14, Mead PS15, Mongodin EF16, Pillai S17, Rao P7, Robinson WH18, Roth KM7, Schriefer ME15, Slezak T19, Snyder JL20, Steere AC21, Witkowski J22, Wong SJ23, Branda JA24.


1 Department of Medicine, Rutgers New Jersey Medical School, Newark.

2 Laboratory Corporation of America, Burlington, North Carolina.

3 Qiagen, Inc., Germantown, Maryland.

4 Scientific Affairs, LLC, Atlanta, Georgia.

5 Department of Microbiology/Immunology, New York Medical College, Valhalla.

6 Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.

7 Office of In Vitro Diagnostics and Radiological Health, Food and Drug Administration, Department of Health and Human Services, Silver Spring, Maryland.

8 Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis.

9 Viramed Biotech AG, Planegg, Germany.

10 L2 Diagnostics, LLC, New Haven, Connecticut.

11 Kephera Diagnostics, Wellesley, Massachusetts.

12 Roche Diagnostics, Pleasanton, California.

13 Center for Applied Proteomics and Molecular Medicine, College of Science, George Mason University, Manassas, Virginia.

14 Clinical Studies Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

15 Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado.

16 Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore.

17 Office of Laboratory Science and Safety, US Food and Drug Administration, Department of Health and Human Services, Silver Spring, Maryland.

18 Department of Medicine, Stanford University School of Medicine, California.

19 Lawrence Livermore National Laboratory, California.

20 T2 Biosystems, Inc., Lexington, Massachusetts.

21 Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston.

22 Cold Spring Harbor Laboratory, New York.

23 Wadsworth Center, New York State Department of Health, Albany.

24 Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston.



Lucy Barnes

AfterTheBite@gmail.com